Cantargia AB (publ) (STO:CANTA)

Market Cap	390.32M
Revenue (ttm)	n/a
Net Income (ttm)	-161.65M
Shares Out	248.61M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,434
Average Volume	376,222
Open	1.568
Previous Close	1.500
Day's Range	1.500 - 1.570
52-Week Range	1.142 - 5.200
Beta	1.87
RSI	60.37
Earnings Date	May 13, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA